Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies

Abstract Chimeric antigen receptor (CAR)-T cell therapies have been approved by FDA to treat relapsed or refractory hematological malignancies. However, the adverse effects of CAR-T cell therapies are complex and can be challenging to diagnose and treat. In this review, we summarize the major advers...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Chieh Yang, John Nguyen, Yun Yen
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMC 2023-10-01
Serie:	Journal of Biomedical Science
Soggetti:	Chimeric antigen receptor (CAR)-T cell therapies Cytokine release syndrome Immune effector cell-associated neurotoxicity syndrome Macrophage activation syndrome
Accesso online:	https://doi.org/10.1186/s12929-023-00982-8
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!